Heathcliff Dorado García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heathcliff Dorado García has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
- Anton George Henssen
Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany
118 shared publications - Johannes Hubertus Schulte
Charité-Universitätsmedizin Berlin 17 Department of Pediatric Oncology/Hematology Berlin, Germany
115 shared publications - Yi Bei
Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
114 shared publications - Angelika Eggert
Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
112 shared publications - Kerstin Haase
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom
112 shared publications - Rocío Chamorro González
Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
111 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Table 6 lists the quantifications of IHC markers in NB PDX.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Table 6 lists the quantifications of IHC markers in NB PDX.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 1 shows cell viability assays of various pediatric cancer cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 1 shows cell viability assays of various pediatric cancer cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 7 depicts the overall survival of each pediatric cancer entity under elimusertib treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 7 depicts the overall survival of each pediatric cancer entity under elimusertib treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 5 shows all tumor volume curves of the PDXs used in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 5 shows all tumor volume curves of the PDXs used in this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Table 3 shows statistics for all tumor volume curves.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Table 3 shows statistics for all tumor volume curves.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Table 5 lists the quantifications of IHC markers in EWS and OS PDX.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Table 5 lists the quantifications of IHC markers in EWS and OS PDX.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 11 displays the quantification of each IHC marker in each PDX tested.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 11 displays the quantification of each IHC marker in each PDX tested.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 6 displays the body weight curves of all PDX-bearing mice over the course of treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 6 displays the body weight curves of all PDX-bearing mice over the course of treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Table 2 lists characteristics of PDX origin.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Table 2 lists characteristics of PDX origin.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 13 depicts the correlation of baseline IHC marker expression to treatment response.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 13 depicts the correlation of baseline IHC marker expression to treatment response.